GlycoMimetics Inc (GLYC)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | BIOTECHNOLOGY & LIFE SCIENCES |
| SIC: | PHARMACEUTICAL PREPARATIONS |
| CEO: | Harout Semerjian |
| Employees: | 50 |
| Web site: | glycomimetics.com |
|
9708 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
240-243-1201
| |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
GlycoMimetics, Inc. focuses on the discovery and development of novel glycomimetic drugs. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML.
Please log in first to see chart